Citius Pharmaceuticals (CTXR) News Today $0.70 +0.03 (+4.16%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.69 -0.01 (-1.58%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?May 24 at 8:31 AM | insidermonkey.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Given Consensus Recommendation of "Hold" by BrokeragesMay 23 at 4:02 AM | americanbankingnews.comCitius Pharmaceuticals Inc.May 19, 2026 | barrons.comCitius Pharmaceuticals' (CTXR) "Buy" Rating Reaffirmed at HC WainwrightMay 19, 2026 | americanbankingnews.comCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | prnewswire.comCitius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12May 15, 2026 | msn.comCitius Expands LYMPHIR Access with First European ShipmentMay 1, 2026 | theglobeandmail.comCitius Oncology Ships First International Order of LYMPHIR™ to EuropeApril 29, 2026 | prnewswire.comCitius Pharmaceuticals Raises $5 Million in Securities OfferingApril 27, 2026 | theglobeandmail.comCitius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesApril 24, 2026 | prnewswire.comWhat's Behind The Drop In Citius Pharmaceuticals?April 24, 2026 | benzinga.comCitius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesApril 24, 2026 | prnewswire.comWe Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) SoonApril 21, 2026 | finance.yahoo.comCitius Pharmaceuticals Announces 2026 Annual Stockholder Meeting ResultsApril 11, 2026 | theglobeandmail.comCitius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentMarch 31, 2026 | finance.yahoo.comCitius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentMarch 31, 2026 | prnewswire.comCitius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsMarch 24, 2026 | finance.yahoo.comCitius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsMarch 24, 2026 | prnewswire.comCitius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic CancersMarch 10, 2026 | prnewswire.comCitius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIRMarch 7, 2026 | finance.yahoo.comCitius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell LymphomaMarch 4, 2026 | prnewswire.comCitius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development ProgramFebruary 24, 2026 | finance.yahoo.comCitius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development ProgramFebruary 24, 2026 | prnewswire.comCitius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIRFebruary 13, 2026 | finanznachrichten.deCitius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™February 13, 2026 | prnewswire.comCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™February 13, 2026 | prnewswire.comCitius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with UnipharFebruary 11, 2026 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateDecember 23, 2025 | prnewswire.comCitius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdateDecember 23, 2025 | prnewswire.comCitius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesDecember 10, 2025 | prnewswire.comCitius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesDecember 9, 2025 | prnewswire.comD Boral Capital maintains Citius Pharmaceuticals (CTXR) buy recommendationDecember 5, 2025 | msn.comCitius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimDecember 4, 2025 | prnewswire.comCitius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)December 1, 2025 | prnewswire.comCitius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual MeetingNovember 25, 2025 | prnewswire.comCitius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI IntegrationNovember 21, 2025 | prnewswire.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Is Expected To Breakeven In The Near FutureNovember 12, 2025 | finance.yahoo.comCitius Pharmaceuticals Announces LYMPHIR Commercialization PlansOctober 23, 2025 | msn.comCitius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesOctober 21, 2025 | prnewswire.comCitius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq RulesOctober 21, 2025 | prnewswire.comCitius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial LaunchOctober 21, 2025 | finance.yahoo.comCitius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 ConferencesOctober 17, 2025 | prnewswire.comCitius Oncology signs exclusive commercialization agreement with EVERSANAOctober 16, 2025 | msn.comCitius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™October 16, 2025 | prnewswire.comCitius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementSeptember 10, 2025 | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementSeptember 9, 2025 | prnewswire.comCitius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR LaunchAugust 22, 2025 | prnewswire.comCitius Posts Wider Loss in Fiscal Q3August 14, 2025 | theglobeandmail.comCitius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last yearAugust 12, 2025 | msn.com Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTXR Media Mentions By Week CTXR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼0.880.45▲Average Medical News Sentiment CTXR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼142▲CTXR Articles Average Week Get the Latest News and Ratings for CTXR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ENTX News Today DWTX News Today IMA News Today ZSQR News Today FLNA News Today CING News Today BYSI News Today HYFT News Today TIL News Today KALA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
